Equities research analysts expect Medidata Solutions (NASDAQ:MDSO) to report $0.40 earnings per share (EPS) for the current quarter, Zacks reports. Seven analysts have made estimates for Medidata Solutions’ earnings. The lowest EPS estimate is $0.39 and the highest is $0.42. Medidata Solutions posted earnings per share of $0.31 during the same quarter last year, which would suggest a positive year over year growth rate of 29%. The company is expected to issue its next earnings results on Tuesday, July 17th.
According to Zacks, analysts expect that Medidata Solutions will report full-year earnings of $1.72 per share for the current year, with EPS estimates ranging from $1.67 to $1.76. For the next year, analysts forecast that the company will report earnings of $2.10 per share, with EPS estimates ranging from $1.94 to $2.25. Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that cover Medidata Solutions.
Medidata Solutions (NASDAQ:MDSO) last issued its quarterly earnings data on Thursday, April 19th. The company reported $0.40 earnings per share for the quarter, beating analysts’ consensus estimates of $0.35 by $0.05. Medidata Solutions had a return on equity of 11.36% and a net margin of 7.96%. The firm had revenue of $149.20 million during the quarter, compared to analyst estimates of $146.73 million. During the same quarter last year, the firm earned $0.31 EPS. Medidata Solutions’s quarterly revenue was up 16.9% on a year-over-year basis.
MDSO has been the subject of a number of recent analyst reports. Zacks Investment Research lowered Medidata Solutions from a “buy” rating to a “hold” rating in a research note on Thursday, February 15th. Royal Bank of Canada set a $82.00 price objective on Medidata Solutions and gave the company a “hold” rating in a research note on Thursday, February 8th. ValuEngine upgraded Medidata Solutions from a “sell” rating to a “hold” rating in a research note on Thursday, April 12th. Needham & Company LLC lowered their price objective on Medidata Solutions to $75.00 and set a “buy” rating for the company in a research note on Friday, February 9th. Finally, Morgan Stanley lowered Medidata Solutions from an “overweight” rating to a “hold” rating and set a $79.00 price objective for the company. in a research note on Monday. Five investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $83.71.
Medidata Solutions traded up $0.15, reaching $75.68, during mid-day trading on Friday, according to Marketbeat.com. 853 shares of the company’s stock traded hands, compared to its average volume of 670,057. Medidata Solutions has a 1-year low of $59.60 and a 1-year high of $85.92. The company has a quick ratio of 1.63, a current ratio of 1.63 and a debt-to-equity ratio of 0.18. The firm has a market cap of $4.50 billion, a PE ratio of 89.13, a price-to-earnings-growth ratio of 3.81 and a beta of 1.49.
In related news, CEO Tarek Sherif sold 26,836 shares of the firm’s stock in a transaction that occurred on Monday, March 12th. The stock was sold at an average price of $70.25, for a total value of $1,885,229.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Rouven Bergmann sold 4,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 19th. The stock was sold at an average price of $71.50, for a total value of $286,000.00. Following the completion of the sale, the chief financial officer now directly owns 93,744 shares in the company, valued at approximately $6,702,696. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 43,231 shares of company stock worth $3,031,999. 4.70% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in MDSO. Dimensional Fund Advisors LP lifted its holdings in shares of Medidata Solutions by 40.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 93,853 shares of the company’s stock worth $7,327,000 after purchasing an additional 27,264 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in shares of Medidata Solutions by 6.3% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 347,388 shares of the company’s stock worth $22,014,000 after purchasing an additional 20,438 shares during the last quarter. Frontier Capital Management Co. LLC lifted its holdings in shares of Medidata Solutions by 12.0% in the 4th quarter. Frontier Capital Management Co. LLC now owns 54,912 shares of the company’s stock worth $3,480,000 after purchasing an additional 5,863 shares during the last quarter. Conestoga Capital Advisors LLC lifted its holdings in shares of Medidata Solutions by 10.9% in the 4th quarter. Conestoga Capital Advisors LLC now owns 735,957 shares of the company’s stock worth $46,638,000 after purchasing an additional 72,195 shares during the last quarter. Finally, Strs Ohio lifted its holdings in shares of Medidata Solutions by 13.9% in the 4th quarter. Strs Ohio now owns 163,797 shares of the company’s stock worth $10,379,000 after purchasing an additional 20,000 shares during the last quarter.
Medidata Solutions Company Profile
Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development of new therapies. The company's platform solutions include data capture and management and trial planning and management.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.